Biotech Values

[mcbio]

That’s a repackaged version of a Barron’s article from Dec 2010 by the same author: #msg-57498987. FWIW

If one has reasonable confidence that MNTA's mC is going to win approval and that MNTA will ultimately prevail in court, I can't imagine that TEVA is a great buy in front of those events. Given that Copaxone accounts for a third of TEVA's profits, I assume the stock will take a hit on just one of those key events. Perhaps the better time to buy TEVA would be after one or both of those events (assuming they come to fruition). We would of course have to weigh the reduced revenue from Copaxone, in light of a generic, with the new valuation at that time.